Details for Patent: 10,888,544

Which drugs does patent 10,888,544 protect, and when does it expire?

Patent 10,888,544 protects CERDELGA and is included in one NDA.

This patent has fifteen patent family members in thirteen countries.

Summary for Patent: 10,888,544

Title:	Methods for treating Gaucher disease
Abstract:	Methods for treating Gaucher disease in patients with renal or hepatic impairment.
Inventor(s):	Li; Jing (Bridgewater, NJ), Peterschmitt; M. Judith (Watertown, MA), Kanamaluru; Vanaja (Bridgewater, NJ), Chen; Jun (Bridgewater, NJ), Gaemers; Sebastiaan J. M. (Naarden, NL), Rudin; Dan (Cambridge, MA)
Assignee:	GENZYME CORPORATION (Cambridge, MA)
Application Number:	16/219,064
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,888,544

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes						LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MODERATE TO SEVERE RENAL IMPAIRMENT
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes						LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MILD HEPATIC IMPAIRMENT AND ARE CONCURRENTLY TAKING A STRONG OR MODERATE CYP3A INHIBITOR

International Family Members for US Patent 10,888,544

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018386182
Brazil	112020011056
Canada	3083663
China	111479591
China	116139130